IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Rating of “Moderate Buy” by Analysts

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has been assigned an average recommendation of “Moderate Buy” from the sixteen brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $45.50.

A number of research analysts have recently issued reports on the stock. BTIG Research restated a “buy” rating and issued a $62.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, October 21st. Barclays began coverage on shares of IDEAYA Biosciences in a research note on Thursday, September 4th. They set an “overweight” rating and a $40.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Wednesday, October 8th. Citigroup reaffirmed a “buy” rating on shares of IDEAYA Biosciences in a report on Tuesday, September 9th. Finally, Stephens reiterated an “overweight” rating and set a $45.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, September 9th.

IDEAYA Biosciences Trading Down 0.2%

Shares of NASDAQ IDYA opened at $31.95 on Thursday. The company has a market capitalization of $2.80 billion, a price-to-earnings ratio of -17.18 and a beta of 0.14. IDEAYA Biosciences has a twelve month low of $13.45 and a twelve month high of $33.64. The business has a 50 day simple moving average of $27.89 and a 200-day simple moving average of $24.01.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $1.45. The firm had revenue of $207.83 million for the quarter, compared to the consensus estimate of $59.98 million. As a group, equities analysts predict that IDEAYA Biosciences will post -3.07 earnings per share for the current year.

Hedge Funds Weigh In On IDEAYA Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of IDYA. Vanguard Group Inc. grew its position in shares of IDEAYA Biosciences by 0.3% during the first quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company’s stock worth $83,417,000 after acquiring an additional 14,535 shares during the last quarter. Geode Capital Management LLC boosted its stake in IDEAYA Biosciences by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 2,113,164 shares of the company’s stock valued at $44,424,000 after purchasing an additional 33,286 shares during the period. Fiera Capital Corp grew its position in IDEAYA Biosciences by 20.0% in the 3rd quarter. Fiera Capital Corp now owns 1,837,967 shares of the company’s stock worth $50,011,000 after purchasing an additional 305,698 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of IDEAYA Biosciences by 4.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,238,094 shares of the company’s stock valued at $26,025,000 after purchasing an additional 50,000 shares during the period. Finally, Candriam S.C.A. increased its stake in shares of IDEAYA Biosciences by 10.8% in the third quarter. Candriam S.C.A. now owns 1,012,967 shares of the company’s stock valued at $27,563,000 after purchasing an additional 98,567 shares during the period. Institutional investors and hedge funds own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.